摘要
目的:观察骨巨细胞瘤(GCT)中血管内皮生长因子(vascular endothelium growth factor,VEGF)、转录调控因子(Ets-1)的表达,探讨其临床意义,并作相关性研究。方法:30例骨巨细胞瘤标本分别按照Jaffe病理分级、临床分期、有无复发进行分组。应用S-P免疫组化方法检测标本组中的VEGF和Ets-1的表达。结果:30例标本中复发10例,复发率为33.3%,VEGF和Ets-1在GCT中的阳性表达率分别为70%(21/30)和36.7%(11/30),Ets-1和VEGF在临床分期及预后各组中的表达差异有统计学意义(P<0.05)。而在Jaffe病理分级组中的表达差异无统计学意义(P>0.05)。结论:VEGF和Ets-1在GCT中的表达与GCT的临床分期和复发有关,有助于评估肿瘤的预后。
Objective： To explore the expression of vascular endothelium growth factor and Ets-1 in giant cell tumor of bone. Methods： 30 specimens were divided according to staging system and Jaffe pathological gradation of GGT and whether recurred or metastasized. VEGF and Ets-1 protein from tumor specimen were examined by immunohistochemistry S-P technique. Results： The level of the expression of VEGF and Ets-1 in giant cell tumor of bone was 70% （21/30） and 36.7% （11/30） respectively, the positive expression of VEGF and Ets-1 was relevant to the clinical stages and prognosis （P〈0.05）.However; there was no relativity between positive expression of Ets-1 and VEGF and pathological gradation of GCT（PM）.05）. Conclusion Expression of Ets-1 and VEGF in GCT is highly related to clinical stages and Prognosis but not to its pathological gradation.
出处
《中国医药导报》
CAS
2009年第7期14-15,共2页
China Medical Herald
